Sjoerd Rodenhuis

Suggest Changes
Learn More
PURPOSE Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas. Combining doxorubicin with standard-dose ifosfamide has not been shown to improve survival and is(More)